We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully

Simply Wall St13:03 ET

How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks

Seeking Alpha12:37 ET

William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating

Moomoo NewsMar 27 02:32 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Wave Life Sciences (WVE)

TipRanksMar 26 11:20 ET · Ratings

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

MT NewswiresMar 26 08:36 ET

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis With Cardiomyopathy

GlobeNewswireMar 26 07:30 ET